Nano-X Imaging Ltd
NASDAQ:NNOX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Nano-X Imaging Ltd
NASDAQ:NNOX
|
IL |
|
Kansai Paint Co Ltd
TSE:4613
|
JP |
|
HanesBrands Inc
NYSE:HBI
|
US |
|
B
|
Bertam Alliance Bhd
KLSE:BERTAM
|
MY |
|
S
|
Sweet Poison Spirits Inc
CNSX:SPS
|
CA |
|
enCore Energy Corp
F:6TU
|
US |
|
B
|
Blue Owl Technology Finance Corp
NYSE:OTF
|
US |
Nano-X Imaging Ltd
Nano-X Imaging Ltd. engages in the development of medical imaging systems.
Nano-X Imaging Ltd. engages in the development of medical imaging systems.
Revenue Growth: Nanox reported Q3 2025 revenue of $3.4 million, up from $3.0 million in Q3 2024, with growth driven mainly by teleradiology services.
2026 Guidance: Management reiterated 2026 revenue guidance of more than $35 million, expecting growth to ramp up through the year with a significant ramp in the latter quarters.
Strategic Acquisitions: The acquisition of Vaso Healthcare IT was completed, expanding Nanox's U.S. customer base and bringing in approximately $4 million in annual revenue.
AI Momentum: Nanox emphasized a strategic shift to integrate AI, highlighting new partnerships and expanding clinical trials—especially for lung cancer screening.
Operational Efficiency: The company is focusing on lean operations and expects the AI segment to reach EBITDA breakeven in 2026, with the broader business targeted for 2027.
European Expansion: New distribution agreements in the Czech Republic and France are strengthening Nanox’s presence in Europe.
Product Launch: The next-generation AI-ready Nanox.ARC X system is set to launch at RSNA, aiming to accelerate market penetration.